News zum Sektor Gesundheit aus Norwegen

 

July 13 2026 – Zelluna ASA (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that the first patient has been given the first dose in ZIMA-101, the Company's first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna's lead TCR-NK product candidate....

Omada Health (Nasdaq: OMDA) announced that members of senior management will participate in Canaccord Genuity's 46th annual Growth Conference....

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Reference is made to the stock exchange announcements by Hofseth BioCare ASA ("HBC" or the "Company") on 28 and 29 June 2026 regarding completion of delivery of Offer Shares in tranche 2 (the "T2 Offer Shares") where its subject to an extraordinary general meeting (the "EGM") resolving to inter alia, (i) issue the T2 Offer Shares in the Private Placement and (ii) amend the terms of the Company's B-shares ("B-Shares Amendments")....

Does Omada Health, Inc. (OMDA) have what it takes to be a top stock pick for momentum investors? Let's find out....

IFM Independent Fund Management AG, are a Liechtenstein-based fund management company acting as trustee for the following investment funds:...

Helsinki, Finland - July 07, 2026 - Provet, the flagship veterinary practice management software of Nordhealth AS, has today completed the early implementation phase of onboarding of Vets for Pets (Pets at Home Group's veterinary business), having now onboarded the 50th clinic onto Provet. The achievement reinforces Provet's position as the leading veterinary practice management software in the UK, and reflects strong collaboration between both teams, demonstrating the strength of Provet's deployment methodology, alongside a new hypercare onboarding model designed to give clinics more...

Reference is made to the stock exchange announcements from Hofseth BioCare ASA ("HBC" or the "Company") published on 26 June 2026 and 29 June 2026 regarding a private placement (the "Private Placement") of new ordinary shares ("Offer Shares") at a fixed price per share of NOK 1.30 (the "Offer Price"), which raised gross proceeds of approximately NOK 144.5 million....

Oslo, 2 July 2026: On the basis of the authorization granted by the General Meeting on 23 April 2026 for the Board of Directors of Zelluna ASA (the “Company”, OSE ticker “ZLNA”) to issue shares to employees and board members under a long-term incentive program, the Board of Directors has resolved to grant 12,000 share options to two Board members in the Company....

Oslo, Norway, 30 June 2026: Photocure ASA (OSE: PHO) is today announcing that Chief Financial Officer Erik Dahl will retire after nearly 14 years of dedicated service to the company. To ensure a seamless transition, Erik will remain with Photocure through the end of December 2026. Erik's tenure has been instrumental in shaping Photocure's financial strength and growth. "Erik has been a tremendous asset to our team, and we are deeply grateful for everything he has contributed to the company and our shareholders over the years," said Chief Executive Officer Dan Schneider. "He has guided our...

Hofseth BioCare ASA held its Annual General Meeting on 30 June 2026.All proposals were resolved as presented in the notice issued on 9 June 2026....

Commercial update — second quarter 2026:...

Oslo, 29 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that the Research Council of Norway has approved a grant of NOK 16 million to Zelluna under the Innovation Project for the Industrial Sector (IPN) scheme....

Reference is made to the stock exchange announcements from Hofseth BioCare ASA ("HBC" or the "Company") published on 26 June 2026 and 29 June 2026 regarding a private placement (the "Private Placement") of new ordinary shares ("Offer Shares") at a fixed price per share of NOK 1.30 (the "Offer Price"), which raised gross proceeds of approximately NOK 144.5 million....

Omada Health, Inc. (OMDA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road....

Oslo, 29 June 2026: Reference is made to the stock exchange announcement by Zelluna ASA (the "Company") on 18 June 2026 regarding completion of a private placement of 3,143,958 new shares at a subscription price of NOK 18.50 per share (the "Private Placement"). In connection with the Private Placement, Radforsk Investeringsstiftelse and Gjelsten Holding AS entered into a share lending agreement with ABG Sundal Collier ASA, acting as manager (the “Manager”), and the Company, to facilitate delivery-versus-payment settlement of shares allocated to investors in the Private Placement (the "SLA")....

Reference is made to the stock exchange announcements from Hofseth BioCare ASA ("HBC" or the "Company") published on 26 June 2026 and 29 June 2026 regarding a private placement (the "Private Placement") of new ordinary shares ("Offer Shares") at a fixed price per share of NOK 1.30 (the "Offer Price"), which raised gross proceeds of approximately NOK 144.5 million....

Reference is made to the stock exchange announcements from Hofseth BioCare ASA ("HBC" or the "Company") published on 26 June 2026 and 29 June 2026 regarding a private placement (the "Private Placement") of new ordinary shares ("Offer Shares") at a fixed price per share of NOK 1.30 (the "Offer Price"), which raised gross proceeds of approximately NOK 144.5 million....

Oslo, Norway, 29 June 2026: Reference is made to the stock exchange announcement published by Zelluna ASA (the “Company”) on 18 June 2026 regarding a successfully placed private placement (the “Private Placement”) and a retail offering (the “Retail Offering”) as described therein. Reference is also made to the resolution of the Board of Directors of the Company to issue 2,972,973 new shares in the Company in the Private Placement and 170,985 new shares in the Company in the Retail Offering at a subscription price of NOK 18.50 per share, raising gross proceeds of approximately NOK 58.2 million, pursuant to an authorisation granted by the Company's general meeting on 23 April 2026....

Oslo, 29 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that The Royal Marsden NHS Foundation Trust has been activated as the second clinical site in the ZIMA-101 Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna's lead TCR-NK product candidate....